文献速递糖尿病

Inclisiran降低LDL-C和PCSK9不受糖尿病状态影响:ORION-1随机临床试验

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2018-11-28

ORION-1试验将501例动脉粥样硬化性心血管疾病(ASCVD)或ASCVD风险等效且LDL-C高的受试者随机分配至安慰剂或inclisiran一或两剂组,比较基线及第180天血脂和PCSK9水平。结果显示,无论有无糖尿病,inclisiran均显著降低LDL-C和PCSK9,且安全性类似安慰剂。

要点

  • Inclisiran在有无糖尿病患者中均显著降低LDL-C和PCSK9。
  • Inclisiran治疗组还降低载脂蛋白B、非HDL胆固醇和脂蛋白(a),升高HDL胆固醇。
  • Inclisiran不良事件特征与安慰剂相似,在有无糖尿病组间比例均衡。

核心结论

  • PCSK9靶向的siRNA策略可能为有无糖尿病患者的血脂异常管理提供新治疗选择。

研究设计与样本

  • ORION-1随机临床试验纳入501例有ASCVD或ASCVD风险等效且尽管最大耐受降LDL-C治疗仍LDL-C高的受试者,随机接受一或两剂安慰剂或inclisiran。

主要发现

  • 在无糖尿病组,inclisiran使LDL-C中位数降低28%至52%(P<0.0001,所有剂量);在糖尿病组降低28%至55%(P<0.005,所有剂量)。
  • Inclisiran治疗组PCSK9也显著降低。
  • Inclisiran治疗组载脂蛋白B、非HDL胆固醇和脂蛋白(a)较低,HDL胆固醇较高。
  • Inclisiran不良事件特征与安慰剂相似,有无糖尿病组间不良事件比例均衡。

临床怎么用

  • 对于有ASCVD或风险等效且LDL-C高的患者,无论是否合并糖尿病,可考虑使用inclisiran降低LDL-C和PCSK9。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of inclisiran by diabetes status. RESEARCH DESIGN AND METHODS: ORION-1 (ClinicalTrials.gov, NCT02597127) randomized 501 subjects with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents and high LDL cholesterol (LDL-C), despite maximally tolerated LDL-C-lowering therapies, to one or two doses of placebo or inclisiran. Levels of lipids and proprotein convertase subtilisin/kexin type 9 (PCSK9) at baseline and day 180 were compared. RESULTS: Inclisiran was associated with marked declines in LDL-C (median -28% to -52%, P < 0.0001 and -28% to -55%, P < 0.005 for all doses in the without- and with-diabetes groups, respectively) and PCSK9. The inclisiran-treated groups also had lower apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) but higher HDL cholesterol. Inclisiran had an adverse profile similar to that of placebo, and adverse events were proportionally balanced in the baseline with- and without-diabetes groups. CONCLUSIONS: PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Leiter LA, Teoh H, Kallend D, et al. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care. 2018. PMID: 30487231. doi:10.2337/dc18-1491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。